Understand the source comparison
Follistatin-344 Myths Debunked: Evidence Comparison
The table below contrasts common follistatin-344 claims with what controlled research actually demonstrates. Each myth is evaluated against peer-reviewed findings, mechanism of action, and observed outcomes in structured protocols. Follistatin-344 builds muscl
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts common follistatin-344 claims with what controlled research actually demonstrates. Each myth is evaluated against peer-reviewed findings, mechanism of action, and observed outcomes in structured protocols.
- Follistatin-344 builds muscle without training
- Myostatin inhibition alone drives hypertrophy
- Myostatin suppression is permissive, not causative. Mechanical tension remains the primary driver of muscle protein synthesis
- Training stimulus is non-negotiable; follistatin modulates growth ceiling, doesn't replace load
- Follistatin-344 burns fat directly
- The peptide has lipolytic or thermogenic properties
- No identified mechanism on adipose tissue. Body composition changes reflect increased lean mass, not direct fat oxidation
- Fat loss requires caloric deficit or thermogenic agents; follistatin doesn't directly mobilize fatty acids
- Gains are permanent after short cycles
- Myostatin inhibition creates durable muscle tissue independent of ongoing stimulus
- Exogenous follistatin has 30–35 hour half-life; myostatin regulation normalizes post-cessation. Muscle mass regresses without sustained training and nutrition
- Follistatin is a temporary modulator; gains above genetic baseline require ongoing intervention
- Follistatin-344 works as a standalone agent
- The peptide delivers results without ancillary support
- All controlled models pair follistatin with resistance training, adequate protein (1.6–2.2g/kg), and caloric surplus during growth phases
- Standalone administration produces minimal measurable change in lean mass
- Higher doses produce proportionally greater gains
- Dose-response curve is linear
- Myostatin binding saturates; doses above 200–300mcg show diminishing marginal returns. Side effect risk increases faster than efficacy
- Optimal dosing is narrow; megadosing doesn't overcome training or nutrition deficits